Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is exhibiting promising results in initial patient studies. Ongoing https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/